Q&A: Boyd Discusses How Fox Chase Plans to 'Operationalize' Personalized Medicine
June 17, 2009
Q&A: Boyd Discusses How Fox Chase Plans to 'Operationalize' Personalized Medicine
Jeff Boyd, Fox Chase's chief scientific officer, shared with Pharmacogenomics Reporter the center's plans to leverage its biorepositories and Phase I clinical trial expertise to woo pharma companies and advance personalized cancer drugs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- N-of-One to Provide Interpretation Reports to Physicians for Fox Chase's CancerCode45 Test
February 27, 2013 / Pharmacogenomics Reporter - Fox Chase Debuts CancerCode-45 Test Based on Adapted Ion Torrent AmpliSeq Panel
January 16, 2013 / Clinical Sequencing News - Switching from SOLiD to PGM, Fox Chase Adopts Targeted Sequencing for Cancer Patients
December 21, 2011 / Clinical Sequencing News - Fox Chase Cancer Center to Offer Sequencing Services to Cancer Patients on LifeTech's SOLiD
June 15, 2011 / Clinical Sequencing News - People in the News
June 15, 2011 / Clinical Sequencing News